Cargando…
Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora
Chitooligosaccharides (COS) have a variety of biological activities due to their positively charged amino groups. Studies have shown that COS have antidiabetic effects, but their molecular mechanism has not been fully elucidated. The present study confirmed that COS can reduce hyperglycemia and hype...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024377/ https://www.ncbi.nlm.nih.gov/pubmed/31968646 http://dx.doi.org/10.3390/md18010069 |
_version_ | 1783498421434318848 |
---|---|
author | Wang, Qiutong Jiang, Yajie Luo, Xuegang Wang, Chang Wang, Nan He, Hongpeng Zhang, Tongcun Chen, Liehuan |
author_facet | Wang, Qiutong Jiang, Yajie Luo, Xuegang Wang, Chang Wang, Nan He, Hongpeng Zhang, Tongcun Chen, Liehuan |
author_sort | Wang, Qiutong |
collection | PubMed |
description | Chitooligosaccharides (COS) have a variety of biological activities due to their positively charged amino groups. Studies have shown that COS have antidiabetic effects, but their molecular mechanism has not been fully elucidated. The present study confirmed that COS can reduce hyperglycemia and hyperlipidemia, prevent obesity, and enhance histological changes in the livers of mice with type 2 diabetes mellitus (T2DM). Additionally, treatment with COS can modulate the composition of the gut microbiota in the colon by altering the abundance of Firmicutes, Bacteroidetes, and Proteobacteria. Furthermore, in T2DM mice, treatment with COS can upregulate the cholesterol-degrading enzymes cholesterol 7-alpha-hydroxylase (CYP7A1) and incretin glucagon-like peptide 1 (GLP-1) while specifically inhibiting the transcription and expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the key enzyme in cholesterol synthesis. Furthermore, using an oleic acid-induced hepatocyte steatosis model, we found that HMGCR can be directly transactivated by SET and MYND domain containing 3 (SMYD3), a transcriptional regulator, via 5′-CCCTCC-3′ element in the promoter. Overexpression of SMYD3 can suppress the inhibitory effect of COS on HMGCR, and COS might regulate HMGCR by inhibiting SMYD3, thereby exerting hypolipidemic functions. To the best of our knowledge, this study is the first to illustrate that COS mediate glucose and lipid metabolism disorders by regulating gut microbiota and SMYD3-mediated signaling pathways. |
format | Online Article Text |
id | pubmed-7024377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70243772020-03-11 Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora Wang, Qiutong Jiang, Yajie Luo, Xuegang Wang, Chang Wang, Nan He, Hongpeng Zhang, Tongcun Chen, Liehuan Mar Drugs Article Chitooligosaccharides (COS) have a variety of biological activities due to their positively charged amino groups. Studies have shown that COS have antidiabetic effects, but their molecular mechanism has not been fully elucidated. The present study confirmed that COS can reduce hyperglycemia and hyperlipidemia, prevent obesity, and enhance histological changes in the livers of mice with type 2 diabetes mellitus (T2DM). Additionally, treatment with COS can modulate the composition of the gut microbiota in the colon by altering the abundance of Firmicutes, Bacteroidetes, and Proteobacteria. Furthermore, in T2DM mice, treatment with COS can upregulate the cholesterol-degrading enzymes cholesterol 7-alpha-hydroxylase (CYP7A1) and incretin glucagon-like peptide 1 (GLP-1) while specifically inhibiting the transcription and expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the key enzyme in cholesterol synthesis. Furthermore, using an oleic acid-induced hepatocyte steatosis model, we found that HMGCR can be directly transactivated by SET and MYND domain containing 3 (SMYD3), a transcriptional regulator, via 5′-CCCTCC-3′ element in the promoter. Overexpression of SMYD3 can suppress the inhibitory effect of COS on HMGCR, and COS might regulate HMGCR by inhibiting SMYD3, thereby exerting hypolipidemic functions. To the best of our knowledge, this study is the first to illustrate that COS mediate glucose and lipid metabolism disorders by regulating gut microbiota and SMYD3-mediated signaling pathways. MDPI 2020-01-20 /pmc/articles/PMC7024377/ /pubmed/31968646 http://dx.doi.org/10.3390/md18010069 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Qiutong Jiang, Yajie Luo, Xuegang Wang, Chang Wang, Nan He, Hongpeng Zhang, Tongcun Chen, Liehuan Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora |
title | Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora |
title_full | Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora |
title_fullStr | Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora |
title_full_unstemmed | Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora |
title_short | Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora |
title_sort | chitooligosaccharides modulate glucose-lipid metabolism by suppressing smyd3 pathways and regulating gut microflora |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024377/ https://www.ncbi.nlm.nih.gov/pubmed/31968646 http://dx.doi.org/10.3390/md18010069 |
work_keys_str_mv | AT wangqiutong chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora AT jiangyajie chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora AT luoxuegang chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora AT wangchang chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora AT wangnan chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora AT hehongpeng chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora AT zhangtongcun chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora AT chenliehuan chitooligosaccharidesmodulateglucoselipidmetabolismbysuppressingsmyd3pathwaysandregulatinggutmicroflora |